A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer

SIMPLE SUMMARY: Prior clinical studies showed modest activity for single agent everolimus and somatostatin analogues in different subtypes of thyroid cancer; the combination of everolimus and somatostatin analogue was synergistic in preclinical models of thyroid cancer. This randomized trial showed...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauman, Julie E., Chen, Zhengjia, Zhang, Chao, Ohr, James P., Ferris, Robert L., McGorisk, Gerald M., Brandt, Stephen, Srivatsa, Sumathi, Chen, Amy Y., Steuer, Conor E., Shin, Dong M., Saba, Nabil F., Khuri, Fadlo R., Owonikoko, Taofeek K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179856/
https://www.ncbi.nlm.nih.gov/pubmed/35681620
http://dx.doi.org/10.3390/cancers14112639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179856/
https://www.ncbi.nlm.nih.gov/pubmed/35681620
http://dx.doi.org/10.3390/cancers14112639

Ejemplares similares